Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2001 Mar;56(3):237–241. doi: 10.1136/thorax.56.3.237

Cystic fibrosis

P Robinson 1
PMCID: PMC1758774  PMID: 11182019

Full Text

The Full Text of this article is available as a PDF (95.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong D. S., Grimwood K., Carzino R., Carlin J. B., Olinsky A., Phelan P. D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995 Jun 17;310(6994):1571–1572. doi: 10.1136/bmj.310.6994.1571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balfour-Lynn I. M., Klein N. J., Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child. 1997 Aug;77(2):124–130. doi: 10.1136/adc.77.2.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Braggion C., Cappelletti L. M., Cornacchia M., Zanolla L., Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study. Pediatr Pulmonol. 1995 Jan;19(1):16–22. doi: 10.1002/ppul.1950190104. [DOI] [PubMed] [Google Scholar]
  4. Button B. M., Heine R. G., Catto-Smith A. G., Phelan P. D. Postural drainage in cystic fibrosis: is there a link with gastro-oesophageal reflux? J Paediatr Child Health. 1998 Aug;34(4):330–334. doi: 10.1046/j.1440-1754.1998.00236.x. [DOI] [PubMed] [Google Scholar]
  5. Desmond K. J., Schwenk W. F., Thomas E., Beaudry P. H., Coates A. L. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. J Pediatr. 1983 Oct;103(4):538–542. doi: 10.1016/s0022-3476(83)80579-4. [DOI] [PubMed] [Google Scholar]
  6. Eigen H., Rosenstein B. J., FitzSimmons S., Schidlow D. V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995 Apr;126(4):515–523. doi: 10.1016/s0022-3476(95)70343-8. [DOI] [PubMed] [Google Scholar]
  7. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997 May;23(5):330–335. doi: 10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  8. Frederiksen B., Koch C., Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol. 1999 Sep;28(3):159–166. doi: 10.1002/(sici)1099-0496(199909)28:3<159::aid-ppul1>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  9. Gaskin K., Gurwitz D., Durie P., Corey M., Levison H., Forstner G. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr. 1982 Jun;100(6):857–862. doi: 10.1016/s0022-3476(82)80501-5. [DOI] [PubMed] [Google Scholar]
  10. Geddes D. M., Alton E. W. The CF gene: 10 years on. Thorax. 1999 Dec;54(12):1052–1054. doi: 10.1136/thx.54.12.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harrison C. J., Marks M. I., Welch D. F., Sharma B. B., Baker D., Dice J. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatr Pharmacol (New York) 1985;5(1):7–16. [PubMed] [Google Scholar]
  12. Henry R. L., Mellis C. M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992 Mar;12(3):158–161. doi: 10.1002/ppul.1950120306. [DOI] [PubMed] [Google Scholar]
  13. Hudson V. L., Wielinski C. L., Regelmann W. E. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr. 1993 Jun;122(6):854–860. doi: 10.1016/s0022-3476(09)90007-5. [DOI] [PubMed] [Google Scholar]
  14. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr. 1990 May;116(5):714–719. doi: 10.1016/s0022-3476(05)82653-8. [DOI] [PubMed] [Google Scholar]
  15. Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  16. Lewin L. O., Byard P. J., Davis P. B. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol. 1990;43(2):125–131. doi: 10.1016/0895-4356(90)90175-o. [DOI] [PubMed] [Google Scholar]
  17. Lewis P. A. Inferences for health provision from survival data in cystic fibrosis. Arch Dis Child. 1998 Oct;79(4):297–299. doi: 10.1136/adc.79.4.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mahadeva R., Webb K., Westerbeek R. C., Carroll N. R., Dodd M. E., Bilton D., Lomas D. A. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ. 1998 Jun 13;316(7147):1771–1775. doi: 10.1136/bmj.316.7147.1771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McIlwaine P. M., Wong L. T., Peacock D., Davidson A. G. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr. 1997 Oct;131(4):570–574. doi: 10.1016/s0022-3476(97)70064-7. [DOI] [PubMed] [Google Scholar]
  20. Nikolaizik W. H., Schöni M. H. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr. 1996 Feb;128(2):271–274. doi: 10.1016/s0022-3476(96)70407-9. [DOI] [PubMed] [Google Scholar]
  21. Oermann C. M., Sockrider M. M., Konstan M. W. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 1999 Apr;115(4):1053–1058. doi: 10.1378/chest.115.4.1053. [DOI] [PubMed] [Google Scholar]
  22. Phelan P., Hey E. Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80. Arch Dis Child. 1984 Jan;59(1):71–73. doi: 10.1136/adc.59.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Phillips G. E., Pike S. E., Rosenthal M., Bush A. Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux. Eur Respir J. 1998 Oct;12(4):954–957. doi: 10.1183/09031936.98.12040954. [DOI] [PubMed] [Google Scholar]
  24. Ramsey B. W., Pepe M. S., Quan J. M., Otto K. L., Montgomery A. B., Williams-Warren J., Vasiljev-K M., Borowitz D., Bowman C. M., Marshall B. C. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan 7;340(1):23–30. doi: 10.1056/NEJM199901073400104. [DOI] [PubMed] [Google Scholar]
  25. Reisman J. J., Rivington-Law B., Corey M., Marcotte J., Wannamaker E., Harcourt D., Levison H. Role of conventional physiotherapy in cystic fibrosis. J Pediatr. 1988 Oct;113(4):632–636. doi: 10.1016/s0022-3476(88)80370-6. [DOI] [PubMed] [Google Scholar]
  26. Sun L., Jiang R. Z., Steinbach S., Holmes A., Campanelli C., Forstner J., Sajjan U., Tan Y., Riley M., Goldstein R. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med. 1995 Jul;1(7):661–666. doi: 10.1038/nm0795-661. [DOI] [PubMed] [Google Scholar]
  27. Tablan O. C., Chorba T. L., Schidlow D. V., White J. W., Hardy K. A., Gilligan P. H., Morgan W. M., Carson L. A., Martone W. J., Jason J. M. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985 Sep;107(3):382–387. doi: 10.1016/s0022-3476(85)80511-4. [DOI] [PubMed] [Google Scholar]
  28. Waters D. L., Wilcken B., Irwing L., Van Asperen P., Mellis C., Simpson J. M., Brown J., Gaskin K. J. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 1999 Jan;80(1):F1–F7. doi: 10.1136/fn.80.1.f1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Weaver L. T., Green M. R., Nicholson K., Mills J., Heeley M. E., Kuzemko J. A., Austin S., Gregory G. A., Dux A. E., Davis J. A. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child. 1994 Feb;70(2):84–89. doi: 10.1136/adc.70.2.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wright G. L., Harper J. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis. Lancet. 1970 Jan 3;1(7636):9–14. doi: 10.1016/s0140-6736(70)90523-4. [DOI] [PubMed] [Google Scholar]
  31. van Haren E. H., Lammers J. W., Festen J., Heijerman H. G., Groot C. A., van Herwaarden C. L. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995 Mar;89(3):209–214. doi: 10.1016/0954-6111(95)90249-x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES